GLIAGEN LLC, DEVELOPER OF TECHNOLOGIES USED TO TREAT NEURODEGENERATIVE DISEASES

GliaGen is focused on the development of novel diagnostic and therapeutic technologies specifically tailored to treat neurodegenerative diseases.

GliaGen is developing novel treatments for neuroaffective disorders including Multiple Sclerosis, Alzheimers, and Parkinsons; including neurotrauma such as spinal cord injuries.

The Quincy, Mass.-based company has secured platform technology developed by Dr. Leon Carlock and Dr. Maria Cypher at the Center for Molecular Medicine and Genetics, Wayne State University School of Medicine.

In addition to commercializing the patent pending technology, the WSU spinoff will also support further research at Wayne State.

       GliaGen currently employs five people. For more information visit: http://www.gliagen.com


Home | Calendar | Campus Map

 

Center for Molecular Medicine and Genetics • Wayne State University School of Medicine • 3127 Scott Hall • 540 East Canfield • Detroit, MI 48201. Administrative Office: (313) 577-5323 Fax: (313) 577-5218 • Email: info@genetics.wayne.edu • Webmaster: rp@miravtech.com

GLYTAG, LLC, INNOVATIVE DRUG TARGETING SYSTEM FINDS NEW WAY TO FIGHT CANCER

GlyTag has developed a novel drug targeting system that increases a drug’s therapeutic efficacy while reducing its toxicity to non-targeted cells and tissues. Dr. Jeff Loeb of Wayne State University has developed this technology and is working with the WSU Office of Technology Transfer as GlyTag moves forward in its operations.

The GlyTag system takes advantage of one of nature’s own methods of targeting growth factors to specific cells in the body through unique cell surface heparin-sulfate molecules.

A “GlyTag” is a polypeptide sequence specifically designed to target recombinant proteins or other macromolecules to specific cells in the body.

       GlyTag is currently completing pre-clinical testing on a prototype GlyTag fusion protein for treating breast                  cancer. To date, this drug has out-performed the same drug without a GlyTag. For more          information visit: http://www.glytag.com

COMMERCIALIZATION CENTER NEWS

 

  HOME

 

  NEWS

 

  ABOUT THE CCC

 

   ADVISORY BOARD

    Internal Advisors

    External Advisors

 

  EDUCATION/EVENTS

 

   USER LOGIN